细胞耐药性是指癌细胞对抗癌药物产生耐受能力，会大大降低药效，影响治疗效果。细胞耐药性是多种癌症难以治愈的重要原因之一。通过纳米药物载体的装载、运输，抗癌药物能够绕过细胞耐药机制，有效杀灭癌细胞，达到治疗目的。现有纳米药物载体通常由脂质、高聚物金属纳米颗粒或DNA折纸纳米结构构成，分别存在药效提升不明显、药物释放过慢和细胞毒性和成本过高等缺陷。开发高效、廉价、安全、生物相容性好的纳米药物载体是生物医药研究的挑战，具有重要意义。本项目首次系统地以生物相容性好，无细胞毒性的DNA分子为材料，利用基于DNA计算的DNA可控自组装技术发展出一套成本低廉的构建多种DNA纳米载体的新方法；并使用抗性细胞存活实验评估各种载体的载药性能，在细胞学实验基础上建立DNA纳米药物载体载药的数学模型，为生物医学研究和临床应用提供指导。

Drug resistance of cancer cells is one of the main obstacles that impede the efficient treatment on incurable cancers. Delivered by nano drug carriers like lipids, polymers and metal nanoparticles, anti-cancer drugs can circumvent the drug resistance mechanism and kill cancer cells with high efficiency. Current nanocarriers exhibit disadvantages of slow drug release, and high cell toxicity. Thus, it remains a challenge to develop safe, biocompatible, and effective nanocarriers for drug delivery. Here we create a variety of new DNA nanocarriers with a novel method that takes the advantage of programmability and biocompatibility of DNA nanotechnology. Plenty of DNA nanocarriers can be constructed by DNA self-assembly. A mathematic model depicting the interactions among nanocarriers, drugs and cells will be constructed based on further cell viability experiments.